X

Trial Profile

ADherence Assessment with Glivec: Indicators and Outcomes

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imatinib (Primary)
Indications Chronic myeloid leukaemia; Gastrointestinal stromal tumours
Focus Therapeutic Use
Acronyms ADAGIO

Most Recent Events

01 Dec 2021 Results (n=169) of post hoc analyses of the ADAGIO study published in the Leukemia Research
08 Jun 2021 Results of a post hoc analysis aimed to model probabilistically the margin of tolerance required to ensure treatment response among patients prescribed Imatinib and the margin, if any, before treatment response is at risk presented at the 57th Annual Meeting of the American Society of Clinical Oncology
09 Nov 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com